How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,860 results for

Chronic Myelogenous Leukemia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia

Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia (...) HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Patients with chronic myelogenous leukemia (CML

2016 Health Technology Assessment (HTA) Database.

2. Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia

Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies (...) on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia. Lansdale

2016 Health Technology Assessment (HTA) Database.

3. Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia

Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia HAYES, Inc. Record Status This is a bibliographic (...) record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Patients with chronic myelogenous leukemia (CML) have an overproduction of partially mature white blood cells of the myeloid

2016 Health Technology Assessment (HTA) Database.

4. Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient (Full text)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient Occurrence of two different hematological malignancies is very infrequent, and it is nevertheless important not to neglect basic examinations in patients follow-up. A 65-year-old patient was referred to our institution for his chronic lymphocytic leukemia (CLL) checkup; we report the different steps leading to the diagnosis of a second hematological malignancy.

2018 Clinical Case Reports PubMed

5. Chronic Myelogenous Leukemia Treatment (PDQ®): Patient Version

Chronic Myelogenous Leukemia Treatment (PDQ®): Patient Version Chronic Myelogenous Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet (...) ]. Bethesda (MD): ; 2002-. Search term Chronic Myelogenous Leukemia Treatment (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: January 30, 2019. This PDQ cancer information summary has current information about the treatment of chronic myelogenous leukemia. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. Editorial Boards write the PDQ cancer information summaries

2018 PDQ - NCI's Comprehensive Cancer Database

6. Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia (Full text)

Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia 29998167 2018 11 14 2341-4545 25 4 2018 Jun GE Portuguese journal of gastroenterology GE Port J Gastroenterol Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia. 198-200 10.1159/000481538 Perdigoto David N DN Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal. Lopes Sandra S Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal (...) . Portela Francisco F Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal. Cipriano Maria Augusta MA Pathology Department, Coimbra Hospital and University Center, Coimbra, Portugal. Tomé Luís L Gastroenterology Department, Coimbra Hospital and University Center, Coimbra, Portugal. eng Journal Article 2017 10 28 Switzerland GE Port J Gastroenterol 101685861 2387-1954 Chronic myelogenous leukemia Colitis Dasatinib Hematochezia 2017 07 06 2017 08 22 2018 7 13 6 0 2018 7

2017 GE Portuguese journal of gastroenterology PubMed

7. Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia (Full text)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia The availability of kinase and other small-molecule inhibitors to treat hematologic malignancies is increasing. Accordingly, novel regimens that employ these therapeutics are rapidly evolving. Herein we report the safe and effective administration of two targeted kinase inhibitors in a patient with concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia.

2017 Clinical Case Reports PubMed

8. Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting (...) registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia The safety and scientific validity of this study is the responsibility of the study sponsor

2018 Clinical Trials

9. Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia (Full text)

Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis. These cells persist in the bone marrow (BM) despite effective inhibition of BCR-ABL kinase activity by tyrosine kinase inhibitors (TKIs). Here we show that although the microRNA (miRNA) miR-126 (...) and leukemia growth, as shown using mouse models of CML in which Mir126a (encoding miR-126) was conditionally knocked out in ECs and/or LSCs. Inhibition of BCR-ABL by TKI treatment caused an undesired increase in endogenous miR-126 levels, which enhanced LSC quiescence and persistence. Mir126a knockout in LSCs and/or ECs, or treatment with a miR-126 inhibitor that targets miR-126 expression in both LSCs and ECs, enhanced the in vivo anti-leukemic effects of TKI treatment and strongly diminished LSC

2018 Nature medicine PubMed

10. Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. (Full text)

Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. Dasatinib is a second-generation tyrosine kinase inhibitor that is indicated for the treatment of patients with chronic myeloid leukemia. Here, we report the case of a man with nephrotic syndrome that was caused by dasatinib.A 40-year-old man with chronic myeloid leukemia was referred to our hospital because of proteinuria 1 month after dasatinib therapy was introduced. A percutaneous kidney

2019 BMC Nephrology PubMed

11. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. (PubMed)

Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. The authors examined Medicare spending and patient spending in older patients with chronic myelogenous leukemia (CML) over the first 5 years from the time of CML diagnosis in the tyrosine kinase inhibitor (TKI) era.Medicare beneficiaries with CML who were diagnosed between 2007 and 2012 at age >65 years were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (805

2019 Cancer

12. Chronic myelogenous leukaemia

Chronic myelogenous leukaemia Chronic myelogenous leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic myelogenous leukaemia Last reviewed: February 2019 Last updated: October 2018 Summary Malignant clonal disorder of haematopoietic stem cells. At presentation, one third of patients may be asymptomatic; if present, symptoms typically include malaise, fever, weight loss, abdominal discomfort, and night (...) sweats. Splenomegaly is the most common physical finding; nearly all patients will have elevated WBC count. Presence of Philadelphia chromosome and /or molecular demonstration of the BCR-ABL transcript confirms diagnosis. Treatment with a BCR-ABL tyrosine kinase inhibitor gives long-term remission without significant adverse events in most patients. Definition Chronic myelogenous leukaemia (CML) is a malignant clonal disorder of the haematopoietic stem cell that results in marked myeloid hyperplasia

2018 BMJ Best Practice

13. Chronic Myelogenous Leukemia Treatment (PDQ®): Health Professional Version

Chronic Myelogenous Leukemia Treatment (PDQ®): Health Professional Version Chronic Myelogenous Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries (...) [Internet]. Bethesda (MD): ; 2002-. Search term Chronic Myelogenous Leukemia Treatment (PDQ®) Health Professional Version PDQ Adult Treatment Editorial Board . Published online: February 8, 2019. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of chronic myelogenous leukemia. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines

2017 PDQ - NCI's Comprehensive Cancer Database

14. Chronic myelogenous leukaemia

Chronic myelogenous leukaemia Chronic myelogenous leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic myelogenous leukaemia Last reviewed: February 2019 Last updated: October 2018 Summary Malignant clonal disorder of haematopoietic stem cells. At presentation, one third of patients may be asymptomatic; if present, symptoms typically include malaise, fever, weight loss, abdominal discomfort, and night (...) sweats. Splenomegaly is the most common physical finding; nearly all patients will have elevated WBC count. Presence of Philadelphia chromosome and /or molecular demonstration of the BCR-ABL transcript confirms diagnosis. Treatment with a BCR-ABL tyrosine kinase inhibitor gives long-term remission without significant adverse events in most patients. Definition Chronic myelogenous leukaemia (CML) is a malignant clonal disorder of the haematopoietic stem cell that results in marked myeloid hyperplasia

2017 BMJ Best Practice

15. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. (Full text)

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved greatly. However, ~30-40% of patients develop resistance to imatinib therapy. Although most resistance is caused by mutations in the BCR-ABL kinase domain, 50-85 (...) % of these patients develop resistance in the absence of new mutations. In these cases, targeting other pathways may be needed to regain clinical response. Using label-free Raman spectromicroscopy, we evaluated a number of leukemia cell lines and discovered an aberrant accumulation of cholesteryl ester (CE) in CML, which was found to be a result of BCR-ABL kinase activity. CE accumulation in CML was found to be a cancer-specific phenomenon as untransformed cells did not accumulate CE. Blocking cholesterol

2017 PLoS ONE PubMed

16. Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy. (Full text)

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy. Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibitor imatinib has become standard therapy for chronic myelogenous leukemia (CML), with most patients reaching total and durable remission. However, a significant fraction of patients develop resistance, commonly due to mutated ABL1 kinase domains

2017 PLoS ONE PubMed

17. PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia. (PubMed)

PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia. Purpose: Leukemia stem cells (LSCs) are an important source of tyrosine kinase inhibitor resistance and disease relapse in patients with chronic myelogenous leukemia (CML). Targeting LSCs may be an attractive strategy to override this thorny problem. Given that EZH2 was overexpressed in primary CML CD34+ cells, our purpose in this study was to evaluate the effects (...) elicited apoptosis and restricted cell growth in CML bulk leukemia cells, but also decreased LSCs in CML CD34+ cells while sparing those from normal bone marrow CD34+ cells. Suppression of EZH2 by GSK126 or specific shRNA prolonged survival of CML mice and reduced the number of LSCs in mice. EZH2 knockdown resulted in elevation of PTEN and led to impaired recruitment of EZH2 and H3K27me3 on the promoter of PTEN gene. The effect of EZH2 knockdown in the CML mice was at least partially reversed by PTEN

2017 Clinical Cancer Research

18. Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) - Full Text (...) , and is defined as death in participants with low-blast AML). Condition or disease Intervention/treatment Phase Myelodysplastic Syndrome Leukemia, Myelomonocytic, Chronic Leukemia, Myeloid, Acute Drug: Azacitidine Drug: Pevonedistat Phase 3 Detailed Description: The drug being tested in this study is called pevonedistat. Pevonedistat is being tested to treat people with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (AML

2017 Clinical Trials

19. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. (PubMed)

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Purpose Immunologic surveillance of minimal residual disease in chronic myelogenous leukemia (CML) may be relevant for long-term control or cure of CML. Little is known about immune-modulatory effects of nilotinib in vivo, potentially predicting response to therapy. Patients and Methods A prospective (...) and comprehensive flow cytometry-based immunomonitoring program paralleled the ENEST1st clinical study, investigating 52 nilotinib-naïve patients with chronic-phase CML. Data were verified in independent validation cohorts. Results T cells of patients with CML at diagnosis expressed low l-selectin (CD62L) levels, which was not a result of proportional aberrations of T-cell subsets. Low numbers of CD62L-expressing CD4+ and CD8+ T cells correlated with higher Sokal score, increased spleen size, and high leukocyte

2017 Journal of Clinical Oncology

20. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. (PubMed)

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. 28744011 2018 06 01 2018 11 13 1476-5551 31 10 2017 10 Leukemia Leukemia NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. 2264-2267 10.1038/leu.2017.235 Sopper S S Department of Hematology and Oncology, Medical University Innsbruck, Innsbruck (...) , Myelogenous, Chronic, BCR-ABL Positive diet therapy Leukemia, Myeloid, Chronic-Phase drug therapy Leukocytes, Mononuclear drug effects Lymphocytes drug effects Pyrimidines therapeutic use 2017 7 27 6 0 2018 6 2 6 0 2017 7 27 6 0 ppublish 28744011 leu2017235 10.1038/leu.2017.235 Blood. 2015 Dec 17;126(25):2720-3 26500342 J Immunol. 2002 Jan 15;168(2):643-50 11777957 Cancer Res. 2015 Jun 1;75(11):2187-99 25832652 Blood. 1998 Dec 15;92(12):4758-63 9845542 Leukemia. 2017 Apr;31(4):829-836 28074067 Leukemia

2017 Leukemia

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>